These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27668844)

  • 1. Sorafenib with ASC-J9
    Xu J; Lin H; Li G; Sun Y; Shi L; Ma WL; Chen J; Cai X; Chang C
    Int J Cancer; 2017 Feb; 140(3):705-717. PubMed ID: 27668844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
    Chao TI; Tai WT; Hung MH; Tsai MH; Chen MH; Chang MJ; Shiau CW; Chen KF
    Cancer Lett; 2016 Feb; 371(2):205-13. PubMed ID: 26679051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
    Su JC; Tseng PH; Wu SH; Hsu CY; Tai WT; Li YS; Chen IT; Liu CY; Chen KF; Shiau CW
    Neoplasia; 2014 Jul; 16(7):595-605. PubMed ID: 25047655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
    Huang CY; Tai WT; Hsieh CY; Hsu WM; Lai YJ; Chen LJ; Shiau CW; Chen KF
    Cancer Lett; 2014 Jul; 349(2):136-43. PubMed ID: 24735751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.
    Wen S; Tian J; Niu Y; Li L; Yeh S; Chang C
    Cancer Lett; 2016 Jul; 376(2):377-86. PubMed ID: 27045473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ASC-J9
    Lin W; Luo J; Sun Y; Lin C; Li G; Niu Y; Chang C
    Cancer Lett; 2018 Jul; 425():21-30. PubMed ID: 29425687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.
    Tai WT; Shiau CW; Chen HL; Liu CY; Lin CS; Cheng AL; Chen PJ; Chen KF
    Cell Death Dis; 2013 Feb; 4(2):e485. PubMed ID: 23392173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
    Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secreted GRP78 activates EGFR-SRC-STAT3 signaling and confers the resistance to sorafeinib in HCC cells.
    Li R; Yanjiao G; Wubin H; Yue W; Jianhua H; Huachuan Z; Rongjian S; Zhidong L
    Oncotarget; 2017 Mar; 8(12):19354-19364. PubMed ID: 28423613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
    Mao J; Yang H; Cui T; Pan P; Kabir N; Chen D; Ma J; Chen X; Chen Y; Yang Y
    Eur J Pharmacol; 2018 Aug; 832():39-49. PubMed ID: 29782854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New therapy with ASC-J9® to suppress the prostatitis via altering the cytokine CCL2 signals.
    Lin SJ; Chou FJ; Lin CY; Chang HC; Yeh S; Chang C
    Oncotarget; 2016 Oct; 7(41):66769-66775. PubMed ID: 27564257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.
    Chen KF; Chen HL; Shiau CW; Liu CY; Chu PY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
    Br J Pharmacol; 2013 Feb; 168(3):658-72. PubMed ID: 22978563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
    Zhou SL; Zhou ZJ; Hu ZQ; Huang XW; Wang Z; Chen EB; Fan J; Cao Y; Dai Z; Zhou J
    Gastroenterology; 2016 Jun; 150(7):1646-1658.e17. PubMed ID: 26924089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.
    Kong J; Kong F; Gao J; Zhang Q; Dong S; Gu F; Ke S; Pan B; Shen Q; Sun H; Zheng L; Sun W
    Mol Cancer; 2014 Jan; 13():7. PubMed ID: 24418169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
    Tai WT; Cheng AL; Shiau CW; Liu CY; Ko CH; Lin MW; Chen PJ; Chen KF
    Mol Cancer Ther; 2012 Feb; 11(2):452-63. PubMed ID: 22180308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.
    Tai WT; Cheng AL; Shiau CW; Huang HP; Huang JW; Chen PJ; Chen KF
    J Hepatol; 2011 Nov; 55(5):1041-8. PubMed ID: 21354226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.
    Zhai B; Jiang X; He C; Zhao D; Ma L; Xu L; Jiang H; Sun X
    Tumour Biol; 2015 Apr; 36(4):2323-34. PubMed ID: 25416439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.